echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Lv Haitao's research group from the Institute of Systems Biomedicine, Shanghai Jiao Tong University, together with the teams from Xi'an Jiaotong University and the University of Macau, published a review of the frontiers of treatment strategies for IBD

    Lv Haitao's research group from the Institute of Systems Biomedicine, Shanghai Jiao Tong University, together with the teams from Xi'an Jiaotong University and the University of Macau, published a review of the frontiers of treatment strategies for IBD

    • Last Update: 2022-05-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Haitao Lv's research group from the Institute of Systems Biomedicine, Shanghai Jiaotong University, in collaboration with teams from Xi'an Jiaotong University and the University of Macau, published a review of the frontiers of IBD treatment strategies in the famous pharmacological journal "Pharmacological Research"
    .

    Inflammatory bowel disease (IBD) is a complex disease induced by multiple factors, and its incidence has gradually increased significantly, seriously affecting the health of a wide range of people
    .
    At present, its pathogenic mechanism analysis and clinical effective treatment still face great challenges, the core reason is the lack of decisive therapeutic targets and candidate effective drug molecules

    .

    Functional Metabolomics is a brand-new frontier interdisciplinary scientific strategy.
    Through the deep cross-integration of metabolomic methods and multidisciplinary frontier technologies, it can break through the description of metabolic phenotypes and realize the deep functional characterization of functional metabolites.
    The analysis of the regulation mechanism will revolutionize the precise diagnosis, molecular typing, pathogenic mechanism analysis and new drug development of complex diseases

    .
    Lv Haitao's research group has been committed to the innovative theory and methodological research of functional metabolomics based on the targeted mass spectrometry strategy,
    and its application in the therapeutic discovery of traditional Chinese medicine and microbial functional natural products for complex diseases (pancreatic cancer, hepatobiliary and pancreatic circulation) and microbial metabolism)
    .

    In recent years, Lyu Haitao's research group from the Institute of Systems Biomedicine, Shanghai Jiao Tong University, Xi'an Jiaotong University, and the University of Macau have collaborated to develop therapeutic discovery research for IBD based on functional metabolomics strategies, that is, based on the co-metabolism of gut microbiota and host functions, Elucidation of new targets and new mechanisms of action of berberine and dihydrogenase in the prevention and treatment of pancreatic cancer chemotherapy complications (side effects) complicated colitis, one of which was selected as a highly cited paper in ESI, which provides information for the treatment of IBD and the development of new drugs Target basis and molecular basis of drug candidates for a new functional metabolic dimension
    .

    Recently, based on the good cooperation foundation, three scientific research teams jointly published a high-level frontier review "Emerging pharmacotherapy for inflammatory bowel diseases"
    .
    In view of the two basic characteristics, 1) the etiology and pathogenesis are complex, and there is a lack of clinical traceability molecular evidence; 2) the complications of various diseases or the manifestations of side effects in the treatment process, such as tumors,

    etc.
    At present, although there are many options for its treatment, the complex etiology and pathogenesis bring great challenges, which seriously affect the health of the population

    .
    This review focuses on the frontiers and latest treatment methods of IBD, sorts out the strategies and titers, and proposes new molecular-level future solutions.
    These research groups are currently conducting cross-sectional research, and in the future, the core focus will be on overcoming the occurrence of cancer and the occurrence of enteritis during radiotherapy and chemotherapy.
    and other toxic side effects

    .
    Researcher Lv Haitao, Professor Wang Yitao and Associate Professor Jing Wanghui are the co-corresponding authors of the paper

    .

    Original link: https:// class="Article-source form-horizontal">


    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.